Bharat Biotech, Biofabri in tech transfer deal for TB vaccine

MUMBAI: Biofabri, a global human vaccine development company, and Hyderabad-based vaccines maker Bharat Biotech have signed a technology transfer agreement for the development of a novel vaccine candidate against tuberculosis.

"The agreement represents a significant milestone in advancing global efforts to expand equitable access to tuberculosis vaccines in line with World Health Organization (WHO) priorities," Bharat Biotech said in a statement. The company will guarantee the production and supply of MTBVAC in more than 70 countries across Africa and south-east Asia, the regions with a high disease burden.

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Based on the initial results, Bharat Biotech is preparing for a pivotal Phase III vaccine efficacy study. It will start recruiting participants in the first quarter of 2026.


"Considering the significant disease burden in India, MTBVAC is poised to be a leading candidate in the TB Mukt Bharat initiative championed by Prime Minister Narendra Modi," Bharat Biotech noted.